Finance Watch: Kyverna, Alto Offerings Could Land In IPO Investors’ Sweet Spot
Follow-Ons And Other Financings Find Support
Public Company Edition: Kyverna and Alto Neuroscience, which may go public in the US this year, have drug candidates in or nearing mid-stage trials. Also, Zealand’s private placement raises $211.4m, Praxis prices a $150m offering and Solid grosses $108.9m in stock sale.
